Pharming Group N.V. (PHAR) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pharming Group N.V. (PHAR) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, losing 29.0% versus a loss of 50.0%. Over five years, PHAR leads with a +39.0% price change compared with -47.1% for SNDX. Pharming Group N.V. is the larger company by market cap ($816.8 million vs $785.0 million), about 1.0 times the size, while Syndax Pharmaceuticals is growing revenue faster (+627.8% vs +26.6%).
Pharming Group N.V. converts more of its revenue into profit, with a net margin of 0.8% versus -165.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHAR | SNDX |
|---|---|---|
| Share price | $11.54 | $8.72 |
| Market cap | $816.78M | $785.05M |
| 1-day change | -5.10% | -4.49% |
| YTD return | -34.69% | -58.50% |
| 1-year return | -29.03% | -50.00% |
| 5-year return | +39.04% | -47.09% |
| P/E ratio (TTM) | 36.06 | — |
| Forward P/E | 64.11 | — |
| EPS (TTM) | $0.32 | $-2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.13M | $172.35M |
| Revenue growth (YoY) | +26.56% | +627.84% |
| Net income (latest FY) | $2.85M | $-285.42M |
| Gross margin | 87.90% | — |
| Operating margin | 6.87% | -158.45% |
| Net margin | 0.76% | -165.60% |
| 52-week high | $21.34 | $25.59 |
| 52-week low | $9.11 | $8.41 |
| Distance from 52-week high | -45.92% | -65.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +209.36% | +306.54% |
| Average volume | 21.33K | 2.63M |
| Shares outstanding | 70.78M | 90.03M |
| Employees | 407 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHAR has outperformed SNDX by 21.0 percentage points over the past year.
- Pharming Group N.V. is more profitable, keeping 0.8 cents of every revenue dollar as net income versus -165.6 cents for Syndax Pharmaceuticals.
- Syndax Pharmaceuticals grew revenue faster in its latest fiscal year (+627.84% vs +26.56%).
About Pharming Group N.V.
PHAR stock →Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
PHAR vs SNDX FAQ
Which is bigger, Pharming Group N.V. or Syndax Pharmaceuticals?
Pharming Group N.V. (PHAR) is larger, with a market capitalization of $816.78M compared with $785.05M for Syndax Pharmaceuticals (SNDX).
Which stock has performed better over the past year, PHAR or SNDX?
PHAR returned -29.03% over the past 12 months, compared with -50.00% for SNDX (price return, excluding dividends). Past performance does not predict future results.
Are Pharming Group N.V. and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.